Open AccessProgrammed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
Author(s) -
Takumi Onoyama,
Yohei Takeda,
Taro Yamashita,
Wataru Hamamoto,
Yuri Sakamoto,
Hiroki Koda,
Soichiro Kawata,
Kazuya Matsumoto,
Hajime Isomoto
Publication year - 2020
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v26.i3.353
Subject(s) - pembrolizumab , nivolumab , medicine , durvalumab , adverse effect , gastroenterology , cancer , immunotherapy
Programmed cell death-1 (PD-1) inhibitor has been indicated for many types of malignancies. However, these inhibitors also cause immune-related adverse events. Hepatobiliary disorder is a phenotype of immune-related adverse event affecting 0%-4.5% of patients treated with PD-1 inhibitors. Recent studies have reported PD-1 inhibitor-related sclerosing cholangitis (SC); however, the associated clinical and pathological features are unclear.